HC Wainwright reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a report published on Tuesday morning. The brokerage currently has a $33.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of TG Therapeutics from a hold rating to a sell rating in a research note on Saturday. BidaskClub raised shares of TG Therapeutics from a sell rating to a hold rating in a research note on Thursday, January 11th. Raymond James Financial reaffirmed a buy rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. B. Riley reaffirmed a buy rating and set a $21.50 price target on shares of TG Therapeutics in a research note on Monday, December 11th. Finally, ValuEngine cut shares of TG Therapeutics from a hold rating to a sell rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $25.50.

TG Therapeutics (NASDAQ TGTX) traded up $0.07 during trading hours on Tuesday, hitting $9.63. 433,335 shares of the stock were exchanged, compared to its average volume of 1,672,810. TG Therapeutics has a fifty-two week low of $4.10 and a fifty-two week high of $15.35. The firm has a market cap of $678.26, a PE ratio of -4.99 and a beta of 1.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. sell-side analysts forecast that TG Therapeutics will post -1.87 earnings per share for the current fiscal year.

In related news, CFO Sean A. Power sold 32,006 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the sale, the chief financial officer now directly owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.70% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of TG Therapeutics by 274.4% in the 2nd quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock worth $26,515,000 after buying an additional 1,933,896 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of TG Therapeutics by 20.6% in the 2nd quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock worth $23,509,000 after buying an additional 398,916 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of TG Therapeutics by 14.3% in the 2nd quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock worth $20,566,000 after buying an additional 255,844 shares in the last quarter. Columbus Circle Investors boosted its position in shares of TG Therapeutics by 9.8% in the 3rd quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock worth $18,165,000 after buying an additional 136,515 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of TG Therapeutics by 29.0% in the 2nd quarter. Northern Trust Corp now owns 598,626 shares of the biopharmaceutical company’s stock worth $6,016,000 after buying an additional 134,463 shares in the last quarter. Institutional investors and hedge funds own 50.41% of the company’s stock.

TRADEMARK VIOLATION WARNING: “TG Therapeutics’ (TGTX) “Buy” Rating Reaffirmed at HC Wainwright” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/01/17/tg-therapeutics-tgtx-buy-rating-reaffirmed-at-hc-wainwright.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Stock Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related stocks with our FREE daily email newsletter.